Original Source: Press Release — Eli Lilly and Company. "Lilly's Jaypirca (pirtobrutinib), the First and Only Approved Non-Covalent (Reversible) BTK Inhibitor, Met Its Primary Endpoint in a Head-to-Head Phase 3 Trial Versus Imbruvica (ibrutinib) in CLL/SLL." July 29, 2025